finasteride and Carcinoma, Anaplastic

finasteride has been researched along with Carcinoma, Anaplastic in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Juan, YS; Lee, HY; Li, CC; Wang, CS; Wu, WJ	1
Akaza, H; Ami, Y; Ideyama, Y; Imada, S; Koiso, K; Takenaka, T	1
Altwein, J; Boyle, P; Denis, LJ; Griffiths, K; Kirby, R; Robertson, C; Schröder, F; Turkes, A	1
Fiorelli, G; Serio, M	1

Reviews

1 review(s) available for finasteride and Carcinoma, Anaplastic

Article	Year
Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. Molecular and cellular endocrinology, 1991, Volume: 78, Issue:1-2 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Azasteroids; Carcinoma; Cell Division; Cells, Cultured; Dihydrotestosterone; Epidermal Growth Factor; Finasteride; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Insulin-Like Growth Factor I; Male; Peptides; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Tumor Cells, Cultured	1991

Article

Year

Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia.

Molecular and cellular endocrinology, 1991, Volume: 78, Issue:1-2

Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Azasteroids; Carcinoma; Cell Division; Cells, Cultured; Dihydrotestosterone; Epidermal Growth Factor; Finasteride; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Insulin-Like Growth Factor I; Male; Peptides; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Tumor Cells, Cultured

1991

Trials

1 trial(s) available for finasteride and Carcinoma, Anaplastic

Article	Year
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. The Prostate, 1999, Jul-01, Volume: 40, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms	1999

Article

Year

Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.

The Prostate, 1999, Jul-01, Volume: 40, Issue:2

Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms

1999

Other Studies

2 other study(ies) available for finasteride and Carcinoma, Anaplastic

Article	Year
5α-reductase inhibitors impact prognosis of urothelial carcinoma. BMC cancer, 2020, Sep-11, Volume: 20, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma; Carcinoma, Transitional Cell; Cholestenone 5 alpha-Reductase; Dutasteride; Finasteride; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Hyperplasia; Receptors, Androgen; Taiwan; Urothelium	2020
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. European urology, 1997, Volume: 31, Issue:3 Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma; Cholestenone 5 alpha-Reductase; Disease Models, Animal; Enzyme Inhibitors; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Immunohistochemistry; Leuprolide; Male; Mice; Mice, Inbred C3H; Oxidoreductases; Rats; Rats, Wistar; Urinary Bladder Neoplasms	1997

Article

Year

5α-reductase inhibitors impact prognosis of urothelial carcinoma.

BMC cancer, 2020, Sep-11, Volume: 20, Issue:1

Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma; Carcinoma, Transitional Cell; Cholestenone 5 alpha-Reductase; Dutasteride; Finasteride; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Hyperplasia; Receptors, Androgen; Taiwan; Urothelium

2020

Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.

European urology, 1997, Volume: 31, Issue:3

Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma; Cholestenone 5 alpha-Reductase; Disease Models, Animal; Enzyme Inhibitors; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Immunohistochemistry; Leuprolide; Male; Mice; Mice, Inbred C3H; Oxidoreductases; Rats; Rats, Wistar; Urinary Bladder Neoplasms

1997